Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta‐analysis

  title={Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta‐analysis},
  author={Imran H. Iftikhar and Lana Alghothani and Lynn Marie Trotti},
  journal={European Journal of Neurology},
To synthesize evidence from available randomized controlled trials (RCT) to compare the efficacies of dopaminergic drugs (pramipexole, ropinirole and rotigotine) and α‐2‐δ ligands (gabapentin enacarbil and pregabalin) for the treatment of restless legs syndrome (RLS). We searched PubMed for all eligible RCTs. Network meta‐analysis using frequentist methodology with random effect models was performed for mean changes in scores on the International RLS Study Group Rating Scale (IRLS) and for… 

Quantitative Comparison of the Efficacies of 5 First‐Line Drugs for Primary Restless Leg Syndrome

In RLS patients with more severe symptoms, the therapeutic effect of dopaminergic agonists tended to be better than that of α‐2‐δ ligands and this effect was found to be associated with baseline symptom severity.

The Efficacy and Safety of Pharmacological Treatments for Restless Legs Syndrome: Systemic Review and Network Meta-Analysis

The pooled results showed that, compared with placebo, only levodopa is inefficient to relieve symptoms of RLS, and Alpha-2-delta ligands and DAs are favorable choices for both primary and secondary RLS because of their significant efficacy and good tolerability.

The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery

Preoperative use of gabapentin was able to reduce acute and chronic postoperative pain, total morphine consumption and the occurrence of nausea following breast cancer surgery.

Therapies for Restless Legs in Parkinson’s Disease

The aim of this article was to review the options and particularities of the treatment of restless legs syndrome (RLS) in Parkinson’s disease (PD), finding that arrangements linked to the peculiar population and pathology of PD are required.

Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis

All drugs except for tralokinumab showed improvements in FEV1, ACQ, and AQLQ and only reslizumab and dupilumab were associated with statistically significant reductions in asthma exacerbation rates.

Acupuncture for restless legs syndrome

A comprehensive systematic review and meta-analysis will evaluate the evidence of randomized controlled trials for acupuncture treatment of Restless legs syndrome to explore whether acupuncture is an effective and safe intervention for RLS.

Therapies for Restless Legs in Parkinson's Disease.

The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation.

The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials

Among antiepileptics and antidepressants, duloxetine appeared to have the most detailed safety for the treatment of peripheral neuropathic pain, and over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation.

Effectiveness and safety of traditional Chinese medicine Shaoyao Gancao Tang for the treatment of restless leg syndrome

A high-quality synthesis of current evidence of Shaoyao Gancao Tang's effectiveness and safety for patients with RLS will be provided.



Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double‐blind, placebo‐controlled pilot study

This pilot study suggests that continuous delivery of rotigotine by means of a patch may provide an effective and well‐tolerated treatment of RLS symptoms both during night and day.

Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Gabapentin enacarbil at 1200 mg significantly improved restless legs syndrome symptoms compared with placebo and Investigator-rated Clinical Global Impression-Improvement scale responses also significantly favored GEn at 1200mg compared with Placebo.

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome

Gabapentin enacarbil 1200 mg once daily significantly reduces restless legs syndrome–associated sleep disturbance and periodic limb movements associated with arousal per hour of sleep and is generally well tolerated in adults with moderate to severe primary restless legs Syndrome.

Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.

This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole.

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

XP13512 1800 mg/day significantly reduced RLS symptoms, improved sleep, and was generally well tolerated in subjects with moderate-to-severe primary RLS across 14 days of treatment.

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome.

Ropinirole treatment significantly improved patients' ability to initiate sleep and the amount of Stage 2 sleep compared with placebo and there were also non-significant trends toward increases in total sleep time and sleep efficiency.